Economic sustainability of immune-checkpoint inhibitors: the looming threat

被引：18

作者：

Verma, Vivek ^{[1
]}

机构：

[1] Allegheny Gen Hosp, Dept Radiat Oncol, Pittsburgh, PA 15212 USA

来源：

NATURE REVIEWS CLINICAL ONCOLOGY | 2018年 / 15卷 / 12期

关键词：

COST-EFFECTIVENESS ANALYSIS; SQUAMOUS-CELL CARCINOMA; NIVOLUMAB; RECURRENT; PEMBROLIZUMAB; DOCETAXEL; HEAD;

D O I：

10.1038/s41571-018-0086-z

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Immune-checkpoint inhibitors (ICIs) are transforming oncology, but the mounting costs of cancer care necessitate concerns regarding economic sustainability. Here, several strategies that clinicians could use to exercise economically prudent administration of ICIs are discussed. These include better appraisal of the cost-effectiveness literature, judicious patient selection, separating statistical from clinical significance, and careful patient counselling.

引用

页码：721 / 722

页数：2

共 10 条

[1] The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC [J].

Aguiar, P. N., Jr. ;

Perry, L. A. ;

Penny-Dimri, J. ;

Babiker, H. ;

Tadokoro, H. ;

de Mello, R. A. ;

Lopes, G. L., Jr. .

ANNALS OF ONCOLOGY, 2017, 28 (09) :2256-2263

[2] First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer [J].

Carbone, D. P. ;

Reck, M. ;

Paz-Ares, L. ;

Creelan, B. ;

Horn, L. ;

Steins, M. ;

Felip, E. ;

van den Heuvel, M. M. ;

Ciuleanu, T. -E. ;

Badin, F. ;

Ready, N. ;

Hiltermann, T. J. N. ;

Nair, S. ;

Juergens, R. ;

Peters, S. ;

Minenza, E. ;

Wrangle, J. M. ;

Rodriguez-Abreu, D. ;

Borghaei, H. ;

Blumenschein, G. R. ;

Villaruz, L. C. ;

Havel, L. ;

Krejci, J. ;

Corral Jaime, J. ;

Chang, H. ;

Geese, W. J. ;

Bhagavatheeswaran, P. ;

Chen, A. C. ;

Socinski, M. A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (25) :2415-2426

[3] Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck [J].

Ferris, R. L. ;

Blumenschein, G., Jr. ;

Fayette, J. ;

Guigay, J. ;

Colevas, A. D. ;

Licitra, L. ;

Harrington, K. ;

Kasper, S. ;

Vokes, E. E. ;

Even, C. ;

Worden, F. ;

Saba, N. F. ;

Iglesias Docampo, L. C. ;

Haddad, R. ;

Rordorf, T. ;

Kiyota, N. ;

Tahara, M. ;

Monga, M. ;

Lynch, M. ;

Geese, W. J. ;

Kopit, J. ;

Shaw, J. W. ;

Gillison, M. L. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19) :1856-1867

[4] Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States [J].

Huang, Min ;

Lou, Yanyan ;

Pellissier, James ;

Burke, Thomas ;

Liu, Frank Xiaoqing ;

Xu, Ruifeng ;

Velcheti, Vamsidhar .

JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (02) :140-150

[5] Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study. [J].

Lopes, Gilberto ;

Wu, Yi-Long ;

Kudaba, Iveta ;

Kowalski, Dariusz ;

Cho, Byoung Chul ;

Castro, Gilberto ;

Srimuninnimit, Vichien ;

Bondarenko, Igor ;

Kubota, Kaoru ;

Lubiniecki, Gregory M. ;

Zhang, Jin ;

Kush, Debra A. ;

Mok, Tony .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (18)

[6] Projections of the Cost of Cancer Care in the United States: 2010-2020 [J].

Mariotto, Angela B. ;

Yabroff, K. Robin ;

Shao, Yongwu ;

Feuer, Eric J. ;

Brown, Martin L. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (02) :117-128

[7] A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing [J].

Matter-Walstra, Klazien ;

Schwenkglenks, Matthias ;

Aebi, Stefan ;

Dedes, Konstantin ;

Diebold, Joachim ;

Pietrini, Mario ;

Klingbiel, Dirk ;

von Moos, Roger ;

Gautschi, Oliver .

JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) :1846-1855

[8] Cost-effectiveness of nivolumab in patients with advanced renal cell carcinoma treated in the United States [J].

McCrea, Charles ;

Johal, Sukhvinder ;

Yang, Shuo ;

Doan, Justin .

EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2018, 7

[9] Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer [J].

Reck, Martin ;

Rodriguez-Abreu, Delvys ;

Robinson, Andrew G. ;

Hui, Rina ;

Csoszi, Tibor ;

Fulop, Andrea ;

Gottfried, Maya ;

Peled, Nir ;

Tafreshi, Ali ;

Cuffe, Sinead ;

O'Brien, Mary ;

Rao, Suman ;

Hotta, Katsuyuki ;

Leiby, Melanie A. ;

Lubiniecki, Gregory M. ;

Shentu, Yue ;

Rangwala, Reshma ;

Brahmer, Julie R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19) :1823-1833

[10] Cost-effectiveness Analysis of Nivolumab for Treatment of Platinum-Resistant Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck [J].

Tringale, Kathryn R. ;

Carroll, Kate T. ;

Zakeri, Kaveh ;

Sacco, Assuntina G. ;

Barnachea, Linda ;

Murphy, James D. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2018, 110 (05) :479-485

← 1 →